After screening the optimal doses of TNF-α and TMAO, four treatment groups were established to further investigate the effects of TNF-α and TMAO on the function of hepatoma Hepa1-6 cells: no treatment control, 50 ng/ml TNF-α alone, 50 μM TMAO alone, and the combination of 50 ng/ml TNF-α and 50 μM TMAO. This evidence concerns the gene TNF and hepatocellular carcinoma.